Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.

Mokhtari RB, Kumar S, Islam SS, Yazdanpanah M, Adeli K, Cutz E, Yeger H.

BMC Cancer. 2013 Aug 8;13:378. doi: 10.1186/1471-2407-13-378.


Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).

Islam SS, Mokhtari RB, Akbari P, Hatina J, Yeger H, Farhat WA.

Target Oncol. 2016 Apr;11(2):209-27. doi: 10.1007/s11523-015-0386-5.


Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M.

Anticancer Drugs. 2013 Jan;24(1):66-72. doi: 10.1097/CAD.0b013e3283584f75. Erratum in: Anticancer Drugs. 2013 Jul;24(6):658.


Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.

Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.

Haematologica. 2011 Aug;96(8):1170-9. doi: 10.3324/haematol.2010.029363. Epub 2011 Jun 28.


Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo.

Wyche TP, Dammalapati A, Cho H, Harrison AD, Kwon GS, Chen H, Bugni TS, Jaskula-Sztul R.

Cancer Gene Ther. 2014 Dec;21(12):518-25. doi: 10.1038/cgt.2014.57. Epub 2014 Nov 21.


Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC.

Endocr Relat Cancer. 2010 Jul 28;17(3):719-29. doi: 10.1677/ERC-10-0097. Print 2010 Sep.


Carbonic anhydrase II mediates malignant behavior of pulmonary neuroendocrine tumors.

Zhou Y, Mokhtari RB, Pan J, Cutz E, Yeger H.

Am J Respir Cell Mol Biol. 2015 Feb;52(2):183-92. doi: 10.1165/rcmb.2014-0054OC.


Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition.

Höhne C, Pickerodt PA, Francis RC, Boemke W, Swenson ER.

Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L178-84. Epub 2006 Aug 25.


Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM.

Cancer. 2008 Mar 15;112(6):1404-14. doi: 10.1002/cncr.23303.


The molecular pathogenesis and management of bronchial carcinoids.

Cakir M, Grossman A.

Expert Opin Ther Targets. 2011 Apr;15(4):457-91. doi: 10.1517/14728222.2011.555403. Epub 2011 Jan 29. Review.


Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway.

Wang L, Tian Z, Yang Q, Li H, Guan H, Shi B, Hou P, Ji M.

Oncotarget. 2015 Sep 22;6(28):25917-31. doi: 10.18632/oncotarget.4542.


Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.

Laitinen KL, Soini Y, Mattila J, Pääkkö P.

Cancer. 2000 Apr 1;88(7):1590-8.


Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.

Li SH, Fu J, Watkins DN, Srivastava RK, Shankar S.

Mol Cell Biochem. 2013 Jan;373(1-2):217-27. doi: 10.1007/s11010-012-1493-6. Epub 2012 Nov 6.


Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.

Larsson DE, Hassan S, Larsson R, Oberg K, Granberg D.

Cancer Chemother Pharmacol. 2009 Dec;65(1):5-12. doi: 10.1007/s00280-009-0997-6. Epub 2009 Apr 19.


Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.

Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, Aparicio S, Winum JY, Supuran CT, Dedhar S.

Oncogene. 2013 Oct 31;32(44):5210-9. doi: 10.1038/onc.2012.550. Epub 2012 Dec 3.


Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro.

Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, Sly WS.

Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4.


Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells.

Cianchi F, Vinci MC, Supuran CT, Peruzzi B, De Giuli P, Fasolis G, Perigli G, Pastorekova S, Papucci L, Pini A, Masini E, Puccetti L.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):710-9. doi: 10.1124/jpet.110.167270. Epub 2010 Jun 2.


Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid.

Pfragner R, Behmel A, Höger H, Beham A, Ingolic E, Stelzer I, Svejda B, Moser VA, Obenauf AC, Siegl V, Haas O, Niederle B.

Anticancer Res. 2009 Jun;29(6):1951-61.


Mastocytes, autofluorescent and silver reducing elements in bronchial carcinoids.

Gloor E, Campiche M, Baumann RP.

Virchows Arch A Pathol Pathol Anat. 1972;357(1):19-28. No abstract available.


Targeting carbonic anhydrase IX with small organic ligands.

Wichert M, Krall N.

Curr Opin Chem Biol. 2015 Jun;26:48-54. doi: 10.1016/j.cbpa.2015.02.005. Epub 2015 Feb 24. Review.


Supplemental Content

Support Center